| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 9482542
[patent_doc_number] => 08728488
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-05-20
[patent_title] => 'Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens'
[patent_app_type] => utility
[patent_app_number] => 13/338529
[patent_app_country] => US
[patent_app_date] => 2011-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 12037
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13338529
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/338529 | Methods of inducing an immune response in a host by administering flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens | Dec 27, 2011 | Issued |
Array
(
[id] => 9901046
[patent_doc_number] => 20150056247
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-02-26
[patent_title] => 'Sequential and repeated immunization with four or more vector-based HIV gene vaccines'
[patent_app_type] => utility
[patent_app_number] => 14/233191
[patent_app_country] => US
[patent_app_date] => 2011-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 3187
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14233191
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/233191 | Sequential and repeated immunization with four or more vector-based HIV gene vaccines | Dec 22, 2011 | Abandoned |
Array
(
[id] => 8138611
[patent_doc_number] => 20120093858
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-04-19
[patent_title] => 'Tat-Based Tolerogen Compositions and Methods for Making and Using Same'
[patent_app_type] => utility
[patent_app_number] => 13/336294
[patent_app_country] => US
[patent_app_date] => 2011-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 11509
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0093/20120093858.pdf
[firstpage_image] =>[orig_patent_app_number] => 13336294
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/336294 | Tat-Based Tolerogen Compositions and Methods for Making and Using Same | Dec 22, 2011 | Abandoned |
Array
(
[id] => 11908238
[patent_doc_number] => 09777042
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-10-03
[patent_title] => 'Method of purifying HIV/SIV Nef from exosomal fusion proteins'
[patent_app_type] => utility
[patent_app_number] => 13/327244
[patent_app_country] => US
[patent_app_date] => 2011-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 12
[patent_no_of_words] => 14944
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13327244
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/327244 | Method of purifying HIV/SIV Nef from exosomal fusion proteins | Dec 14, 2011 | Issued |
Array
(
[id] => 11767911
[patent_doc_number] => 09376486
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-06-28
[patent_title] => 'Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/993983
[patent_app_country] => US
[patent_app_date] => 2011-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 25
[patent_no_of_words] => 17525
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13993983
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/993983 | Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof | Dec 13, 2011 | Issued |
Array
(
[id] => 8536842
[patent_doc_number] => RE043823
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2012-11-20
[patent_title] => 'Human monoclonal antibody against coreceptors for human immunodeficiency virus'
[patent_app_type] => reissue
[patent_app_number] => 13/300340
[patent_app_country] => US
[patent_app_date] => 2011-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 23
[patent_no_of_words] => 26292
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13300340
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/300340 | Human monoclonal antibody against coreceptors for human immunodeficiency virus | Nov 17, 2011 | Abandoned |
Array
(
[id] => 9147841
[patent_doc_number] => 20130302364
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-11-14
[patent_title] => 'HIGHLY IMMUNOGENIC HIV P24 SEQUENCES'
[patent_app_type] => utility
[patent_app_number] => 13/884634
[patent_app_country] => US
[patent_app_date] => 2011-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 15396
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884634
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/884634 | HIGHLY IMMUNOGENIC HIV P24 SEQUENCES | Nov 9, 2011 | Abandoned |
Array
(
[id] => 9435029
[patent_doc_number] => 20140112936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-04-24
[patent_title] => 'METHODS OF NEUTRALIZING VIRAL INFECTION'
[patent_app_type] => utility
[patent_app_number] => 13/884823
[patent_app_country] => US
[patent_app_date] => 2011-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 20020
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13884823
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/884823 | Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41 | Nov 8, 2011 | Issued |
Array
(
[id] => 10629803
[patent_doc_number] => 09347951
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-05-24
[patent_title] => 'Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region'
[patent_app_type] => utility
[patent_app_number] => 13/882041
[patent_app_country] => US
[patent_app_date] => 2011-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 14911
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13882041
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/882041 | Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region | Oct 27, 2011 | Issued |
Array
(
[id] => 10168271
[patent_doc_number] => 09198964
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-12-01
[patent_title] => 'Recombinant subunit dengue virus vaccine'
[patent_app_type] => utility
[patent_app_number] => 13/881423
[patent_app_country] => US
[patent_app_date] => 2011-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 16647
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13881423
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/881423 | Recombinant subunit dengue virus vaccine | Oct 26, 2011 | Issued |
Array
(
[id] => 7776315
[patent_doc_number] => 20120039894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-02-16
[patent_title] => 'IDENTIFICATION OF THERAPEUTIC AGENTS FOR HIV INFECTION'
[patent_app_type] => utility
[patent_app_number] => 13/280070
[patent_app_country] => US
[patent_app_date] => 2011-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 15297
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0039/20120039894.pdf
[firstpage_image] =>[orig_patent_app_number] => 13280070
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/280070 | Method for inhibiting dendritic cell immunoreceptor (DCIR)-mediated human immunodeficiency virus infection comprising administering anti-DCIR antibodies | Oct 23, 2011 | Issued |
Array
(
[id] => 8172398
[patent_doc_number] => 20120107910
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-03
[patent_title] => 'RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 13/279250
[patent_app_country] => US
[patent_app_date] => 2011-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5718
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0107/20120107910.pdf
[firstpage_image] =>[orig_patent_app_number] => 13279250
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/279250 | Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41 | Oct 21, 2011 | Issued |
Array
(
[id] => 8301041
[patent_doc_number] => 20120183597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-07-19
[patent_title] => 'Method of inducing neutralizing antibodies to human immunodeficiency virus'
[patent_app_type] => utility
[patent_app_number] => 13/200865
[patent_app_country] => US
[patent_app_date] => 2011-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 7655
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13200865
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/200865 | Method of inducing neutralizing antibodies to human immunodeficiency virus | Oct 3, 2011 | Abandoned |
Array
(
[id] => 8989721
[patent_doc_number] => 20130217002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-08-22
[patent_title] => 'HIV-1 IGG3 RESPONSE IN ACUTE HIV-1'
[patent_app_type] => utility
[patent_app_number] => 13/877281
[patent_app_country] => US
[patent_app_date] => 2011-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 8732
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13877281
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/877281 | HIV-1 IGG3 RESPONSE IN ACUTE HIV-1 | Oct 2, 2011 | Abandoned |
Array
(
[id] => 11357377
[patent_doc_number] => 09534020
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-01-03
[patent_title] => 'Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide'
[patent_app_type] => utility
[patent_app_number] => 13/876918
[patent_app_country] => US
[patent_app_date] => 2011-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 13798
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13876918
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/876918 | Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide | Sep 27, 2011 | Issued |
Array
(
[id] => 9227117
[patent_doc_number] => 08632782
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-01-21
[patent_title] => 'Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region'
[patent_app_type] => utility
[patent_app_number] => 13/240849
[patent_app_country] => US
[patent_app_date] => 2011-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 16
[patent_no_of_words] => 53296
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13240849
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/240849 | Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region | Sep 21, 2011 | Issued |
Array
(
[id] => 7669108
[patent_doc_number] => 20110318377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-29
[patent_title] => 'Methylated TAT Polypeptides and Methods of Use Thereof'
[patent_app_type] => utility
[patent_app_number] => 13/230540
[patent_app_country] => US
[patent_app_date] => 2011-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 25073
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13230540
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/230540 | Screening method for the identification of inhibitors of HIV Tat methylation by the lysine methyltransferase Set7/9 | Sep 11, 2011 | Issued |
Array
(
[id] => 8232648
[patent_doc_number] => 08198088
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-06-12
[patent_title] => 'Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)'
[patent_app_type] => utility
[patent_app_number] => 13/221952
[patent_app_country] => US
[patent_app_date] => 2011-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 19213
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/198/08198088.pdf
[firstpage_image] =>[orig_patent_app_number] => 13221952
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/221952 | Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs) | Aug 30, 2011 | Issued |
Array
(
[id] => 8532945
[patent_doc_number] => 08309098
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-11-13
[patent_title] => 'Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)'
[patent_app_type] => utility
[patent_app_number] => 13/222020
[patent_app_country] => US
[patent_app_date] => 2011-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 19213
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13222020
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/222020 | Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs) | Aug 30, 2011 | Issued |
Array
(
[id] => 7732480
[patent_doc_number] => 20120015423
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-19
[patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA'
[patent_app_type] => utility
[patent_app_number] => 13/221108
[patent_app_country] => US
[patent_app_date] => 2011-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 19123
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0015/20120015423.pdf
[firstpage_image] =>[orig_patent_app_number] => 13221108
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/221108 | Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) | Aug 29, 2011 | Issued |